Jeffrey L Saver Selected Research

Neuroprotective Agents

10/2023	Clinically important effect sizes for clinical trials using infarct growth reduction as the primary outcome: a systematic review.
7/2023	Circadian variation in stroke onset: Differences between ischemic and hemorrhagic stroke and weekdays versus weekends.
1/2022	Quantifying the amount of greater brain ischemia protection time with pre-hospital vs. in-hospital neuroprotective agent start.
1/2022	Beyond the Golden Hour: Treating Acute Stroke in the Platinum 30 Minutes.
1/2017	Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges.
1/2017	Paramedic Initiation of Neuroprotective Agent Infusions: Successful Achievement of Target Blood Levels and Attained Level Effect on Clinical Outcomes in the FAST-MAG Pivotal Trial (Field Administration of Stroke Therapy - Magnesium).
2/2014	Methodology of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) phase 3 trial: Part 2 - prehospital study methods.
2/2014	Methodology of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) phase 3 trial: Part 1 - rationale and general methods.
1/2014	Magnesium: potential roles in neurovascular disease.
4/2009	Treatment effects for which shift or binary analyses are advantageous in acute stroke trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey L Saver Research Topics

Disease

320	Stroke (Strokes) 05/2024 - 06/2003
257	Ischemic Stroke 05/2024 - 01/2002
40	Infarction (Infarctions) 11/2023 - 01/2005
27	Brain Ischemia (Cerebral Ischemia) 11/2023 - 12/2004
26	Intracranial Hemorrhages (Intracranial Hemorrhage) 02/2024 - 09/2012
21	Cerebral Hemorrhage 04/2024 - 01/2002
21	Hemorrhage 03/2024 - 09/2004
18	Transient Ischemic Attack 01/2023 - 12/2004
17	Atrial Fibrillation 01/2023 - 09/2004
14	Cerebral Infarction 12/2023 - 01/2005
11	Hypertension (High Blood Pressure) 02/2023 - 09/2005
10	Ischemia 01/2023 - 01/2003
9	Myocardial Infarction 05/2024 - 11/2008
8	Intracranial Arteriosclerosis (Cerebral Atherosclerosis) 01/2023 - 01/2012
8	Diabetes Mellitus 01/2020 - 09/2004
7	Arterial Occlusive Diseases (Arterial Occlusive Disease) 12/2023 - 12/2002
7	Heart Failure 01/2023 - 11/2010
7	Pathologic Constriction (Stenosis) 01/2022 - 09/2004
7	Hemorrhagic Stroke 01/2022 - 01/2008
7	Patent Foramen Ovale 12/2018 - 11/2008
6	Embolic Stroke 03/2024 - 01/2014
6	Neurologic Manifestations (Neurological Manifestations) 11/2020 - 01/2008
6	Thrombosis (Thrombus) 06/2014 - 11/2003
5	Atherosclerosis 12/2023 - 01/2008
5	Hematoma 12/2023 - 02/2012
5	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 11/2010
5	Coronary Disease (Coronary Heart Disease) 12/2021 - 11/2010
5	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 08/2019 - 11/2007
4	Hyperglycemia 02/2023 - 01/2016
4	Brain Edema (Cerebral Edema) 01/2022 - 09/2013
4	Edema (Dropsy) 11/2021 - 01/2018
4	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2017 - 12/2004
3	Acute Coronary Syndrome 01/2023 - 06/2011
3	Hyperlipidemias (Hyperlipidemia) 01/2022 - 01/2009
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/2021 - 12/2010
3	Ganglion Cysts (Ganglion) 10/2020 - 01/2019
3	Venous Thrombosis (Deep-Vein Thrombosis) 10/2018 - 09/2013
2	Hypothermia 02/2023 - 01/2020
2	Brain Infarction 01/2023 - 11/2019
2	COVID-19 01/2023 - 10/2020
2	Leukoaraiosis 01/2023 - 07/2012

Drug/Important Bio-Agent (IBA)

72	Tissue Plasminogen Activator (Alteplase)FDA Link 02/2024 - 06/2003
31	MagnesiumIBA 12/2023 - 05/2004
21	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2024 - 11/2006
19	Glucose (Dextrose)FDA LinkGeneric 02/2023 - 05/2007
15	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 01/2005
13	Neuroprotective AgentsIBA 10/2023 - 01/2003
10	Tirofiban (Aggrastat)FDA Link 02/2024 - 01/2022
10	Warfarin (Coumadin)FDA LinkGeneric 01/2023 - 09/2004
9	Biomarkers (Surrogate Marker)IBA 03/2024 - 03/2007
9	Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric 12/2023 - 05/2004
9	Cytidine Triphosphate (CTP)IBA 11/2023 - 01/2017
9	Antihypertensive Agents (Antihypertensives)IBA 01/2023 - 09/2005
9	AnticoagulantsIBA 01/2023 - 09/2004
8	salicylhydroxamic acid (SHAM)IBA 06/2023 - 01/2019
7	Clopidogrel (Plavix)FDA Link 05/2024 - 06/2011
7	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2021 - 10/2007
6	LipidsIBA 10/2021 - 01/2005
6	Indicators and Reagents (Reagents)IBA 01/2020 - 11/2003
5	Tenecteplase FDA Link 12/2023 - 10/2018
5	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2023 - 01/2008
5	Blood Glucose (Blood Sugar)IBA 01/2022 - 09/2012
5	HomocysteineIBA 12/2012 - 07/2008
5	CholesterolIBA 10/2010 - 01/2005
4	Nitroglycerin (Dynamite)FDA LinkGeneric 06/2023 - 01/2016
4	Vitamin K FDA Link 01/2023 - 01/2018
4	antineoplaston A10 (A 10)IBA 12/2021 - 01/2012
3	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 05/2024 - 01/2022
3	edoxabanIBA 03/2024 - 12/2020
3	CreatinineIBA 12/2023 - 05/2007
3	trans-sodium crocetinate (crocetin)IBA 10/2023 - 01/2022
3	Dabigatran FDA Link 01/2023 - 01/2019
3	RivaroxabanIBA 01/2023 - 01/2019
3	Heparin (Liquaemin)FDA LinkGeneric 01/2020 - 09/2013
3	HDL LipoproteinsIBA 01/2020 - 09/2006
3	Folic Acid (Vitamin M)FDA LinkGeneric 01/2018 - 06/2010
3	Pioglitazone (Actos)FDA Link 01/2017 - 01/2017
3	Retinaldehyde (Retinal)IBA 01/2013 - 11/2008
3	HDL CholesterolIBA 08/2011 - 09/2006
3	Complement System Proteins (Complement)IBA 07/2010 - 09/2007
2	fibrin fragment D (D-dimer)IBA 03/2024 - 08/2011
2	danaparoid (Orgaran)FDA Link 01/2024 - 01/2011
2	Glycoproteins (Glycoprotein)IBA 06/2023 - 01/2023
2	apixabanIBA 01/2023 - 12/2020
2	PlacebosIBA 01/2023 - 01/2022

Therapy/Procedure

218	Therapeutics 05/2024 - 12/2002
115	Thrombectomy 03/2024 - 10/2009
26	Stents 11/2021 - 01/2012
23	Thrombolytic Therapy 01/2023 - 01/2002
11	Secondary Prevention 05/2024 - 12/2004
10	Embolectomy 10/2018 - 12/2004
9	Time-to-Treatment 01/2020 - 11/2011
7	Catheters 01/2020 - 11/2003
6	Contraindications 08/2019 - 01/2002
6	Length of Stay 01/2019 - 09/2006
5	Treatment Delay 12/2017 - 04/2014
4	Punctures 02/2024 - 01/2019
3	Aftercare (After-Treatment) 03/2023 - 08/2014
3	Carotid Endarterectomy 01/2014 - 09/2004
2	Anesthesia 02/2024 - 06/2009